Tildrakizumab

Tildrakizumab (trade name Ilumya (US)/Ilumetri (European Union)) is a monoclonal antibody designed for the treatment of immunologically mediated inflammatory disorders.[1] It is approved for the treatment of adult patients with moderate-to-severe plaque psoriasis in the United States and the European Union.[2][3][4] Tildrakizumab was designed to block interleukin-23 (IL-23), a cytokine that plays a key role in managing the immun... [wikipedia]